A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens.

Creator(s)

Rachel Chevalier, Children's Mercy HospitalFollow
Thomas M. Attard, Children's Mercy HospitalFollow
Sara L. Van Driest
Valentina Shakhnovich, Children's Mercy HospitalFollow

Document Type

Editorial

Publication Date

2-2023

Identifier

DOI: 10.1080/17425255.2023.2190883

Journal Title

Expert Opin Drug Metab Toxicol

Volume

19

Issue

2

First Page

53

Last Page

56

Keywords

CYP2C19; Proton pump inhibitors; adverse events; gastroesophageal reflux disease (GERD); interstitial nephritis; pharmacogenetics

Recommended Citation

Chevalier R, Attard T, Van Driest SL, Shakhnovich V. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. Expert Opin Drug Metab Toxicol. 2023;19(2):53-56. doi:10.1080/17425255.2023.2190883